Key Takeaways
- Domestic drag, international strength: Revenue grew 18% YoY, but domestic organic growth ex-Sanofi and FCM was just 4%, while Canada’s Mantra acquisition delivered ~25% like-for-like growth.
- Cardiac restructuring hit the quarter: The Sanofi portfolio integration and cross-pollination of 240+ team members slowed cardiac growth below therapy rates; management expects improvement from Q4.
- Gross margin compressed on mix: Gross margin fell to 60.1% from 62.7% as lower-margin Sanofi business and international product mix weighed, though base business gross contribution held steady YoY.
- Semaglutide ambition is real but crowded: Management is confident of being in the first wave of India launches at loss of exclusivity (March 2026), with vertically integrated API-to-fill/finish capability, but acknowledged others will also be in that wave.
- What to watch next quarter: Whether cardiac growth rebounds as guided, the pace of domestic base business recovery, and any margin sequential improvement after the Q2-to-Q3 decline that missed earlier commentary.
Domestic Business: The Core Problem
- Organic growth stripped bare: Excluding the Sanofi portfolio and OROFER patent expiration impact, domestic organic growth was 4% for the quarter and 6.5% year-to-date, well below the stated ambition of industry-plus growth.
- Cardiac restructuring mechanics: The Sanofi cardio-diabetes portfolio was cross-pollinated across Emcure divisions this quarter, with 240+ Sanofi team members joining; the first six months post-transition focused on stabilization, and synergy work only began this quarter, depressing growth.
- Acute segment weakness: Acute continues to have muted growth industry-wide, and Emcure’s Zuventus subsidiary, which is largely an acute portfolio, underperformed the semi-chronic and chronic Emcure-side portfolio.
- OROFER patent expiry: The expiration pulled down organic growth by an estimated 1–2 percentage points, compounding the acute and restructuring headwinds.
- Chronic vs acute thesis: Satish Mehta observed that generic-generic substitution is making inroads in acute because treatments last only five to seven days, while chronic patients are reluctant to switch once on a medication, a trend he believes favors Emcure’s chronic-heavy mix over time.
Satish Mehta: "Yes, we are doing exceedingly well in the international market but for me, the main objective is to put the domestic market on track and we need to grow more than the industry growth and that is my very immediate goal and objective for which I am giving my undiluted attention to ensure that the domestic growth also picks up in the next few months."
International: The Growth Engine
- Canada delivered standout growth: The Mantra acquisition is fully integrated and doing exceedingly well, with like-for-like growth of approximately 25% for the quarter; management is targeting a mid-teens growth profile going forward with cross-pollinated portfolios.
- Emerging markets ex-ARV: Strong growth driven by LATAM, MENA, and Asia (Sri Lanka, Mauritius, Philippines, Myanmar), supported by a differentiated portfolio of chiral products, biologics, and complex injectables.
- Europe muted as guided: Growth was muted in the current year, consistent with prior guidance; management expects a return to growth next year, targeting high single-digit growth for FY26, with key approvals expected at the start of the fiscal year.
- Liposomal Amphotericin B gaining traction: Filed across several target markets with approvals now flowing through; approved in the UK and doing exceedingly well.
Pipeline & New Bets
- Semaglutide: API already developed in R&D and samples given to the formulation team; management is confident of being in the first wave of India launches at loss of exclusivity (March 2026), with vertically integrated manufacturing from an EU-approved facility for both filling and tablets. The trained metabolic field force and complete supply chain control are cited as advantages. For overseas, Phase 1 targets nearby markets accepting Indian clinical trial data; Phase 2 targets regulated markets with a different strategy. Canada filing is planned but unlikely to be first wave, more likely 8–12 months after.
- Bevacizumab for wAMD: Phase 3 ongoing with a patented delivery device; will be the anchor brand for ophthalmology entry. No competitor has this indication approved on-label in India, though off-label use is rampant globally with reported serious side effects. Beyond wAMD, two or three more ophthalmology indications will be pursued.
- Recombinant Asparaginase: On the verge of DCGI clearance, expected in the next six months; most studies are completed.
- Derma subsidiary Emcutix: Now fully operational with a 200+ person team headed by Satya (former CEO of Galderma); 100% owned by Emcure with no equity given to management. New launches, both in-house and partner products, start from FY26, spanning prescription derma, cosmeceuticals/cosmetology, and a medium-term OTC target. For mAbs in atopic dermatitis and psoriasis, the company is talking to innovator companies for partnerships rather than developing in-house immediately.
- Women’s health: Recently launched products in PCOS and pre/post-menopausal support where a therapy gap existed. Management acknowledged Mankind, post-Bharat Serum acquisition, would be larger in absolute magnitude, but Emcure highlighted its historical leading position.
Satish Mehta: "The Economist is projecting sales of something like a $100 billion for this particular product along with Eli Lily's Mounjaro. So it is anyone's guess."
Margins: Compressed but with a Multi-Year Promise
- Gross margin declined on mix: Gross margin fell 260 bps YoY to 60.1%, driven by business mix: the Sanofi business carries lower margins, and the international vs domestic product mix within the international segment also weighed. Base business gross contribution was stable YoY.
- EBITDA margin improved YoY: Operating leverage and better productivity lifted EBITDA margin despite the gross margin compression.
- Sequential margin miss: Management had earlier indicated margins would sequentially improve from Q2, but Q2 to Q3 actually declined; full-year margin guidance was revised lower on the call.
- Other income hit: A forex loss of approximately ₹7 crores and the absence of a prior-quarter asset sale reduced other income.
- Depreciation and interest: Depreciation increased due to the Mantra acquisition and operationalization of four new plants over the last 18 months; interest cost reduced on lower borrowings.
- Tax rate: Higher due to a one-time prior-period tax charge of ₹15 crores.
- Multi-year margin target: Management expects 300–400 bps improvement in margin profile over a 3–4 year horizon, driven by domestic margin improvement from higher productivity and near-term launches, ramp-up of the four new facilities, and eventual Emcutix scale, though Emcutix will take time to reach decent margins. No absolute margin level was specified.
Vikas Thapar: "we believe that we should definitely be getting about a 300 to 400 basis points improvement in the margin profile over that time horizon. That will be the endeavour."
Balance Sheet & Capital Allocation
- Debt reduction path: Management expects to pare down debt in the next 2–3 quarters and reach a net cash balance sheet by March 2026, subject to no M&A activity.
- R&D spend steady: Will be maintained at 4–5% of revenue.
- Five-year plan framework: Aims to deliver industry-leading growth led by in-house innovation (R&D), M&A, and in-licensing. Large-ticket M&A is focused on India; in-licensing spans India, Canada, and the UK. Focus areas for in-licensing include oncology, nephrology, metabolic, derma, and ophthalmology.
Satish Mehta: "Before listing, we had 20-25 equity holders and now we know the family is more than 140,000 and that puts enormous amount of responsibility on me as CEO, and all of us at Emcure are acutely conscious of our responsibility."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Domestic growth pickup | Grow faster than industry; immediate goal to get domestic growth to pick up | Next few months |
| Cardiac segment improvement | Improvement from current quarter, though may not fully normalize | Q4 FY25 onwards |
| Domestic growth target | In line with industry plus 50–100 bps | Ongoing |
| Recombinant Asparaginase approval | DCGI clearance | Next 6 months |
| Semaglutide India launch | First wave at loss of exclusivity | March 2026 |
| Europe growth return | High single-digit growth | FY26 |
| Canada growth profile | Mid-teens growth | Ongoing |
| Derma new launches (Emcutix) | In-house and partner products | Starting FY26 |
| Margin improvement | 300–400 bps improvement in margin profile | 3–4 year horizon |
| Net cash balance sheet | Subject to no M&A | By March 2026 |
| R&D spend | Maintain at 4–5% of revenue | Ongoing |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue from operations | ₹1,963 cr, +18% YoY |
| Domestic revenue | ₹888 cr, +12% YoY |
| International revenue | ₹1,075 cr, +23% YoY |
| Canada revenue | ₹352 cr, +34% YoY |
| Emerging markets revenue | ₹365 cr, +40% YoY |
| Europe revenue | ₹358 cr, +2% YoY |
| Gross margin | 60.1%, vs 62.7% in Q3 FY24 |
| EBITDA (excl. other income) | ₹362 cr, +23% YoY |
| EBITDA margin | 18.4%, up YoY |
| Adjusted PAT (excl. one-time tax) | ₹171 cr, +43% YoY |
| Reported PAT | ₹156 cr |
| Net debt | ₹600 cr, down from ₹705 cr in Q2 FY25 |
| Working capital days | 96 days, stable |
| Domestic organic growth ex-FCM | 4% (per an analyst's math) |
| PCPM | 6.1, vs 5.6 in Q3 FY24 |
| R&D spend | 4%–5% of revenue |